ALICYN CAMPBELL
Founder & Strategic Lead
Alicyn is widely regarded for her expertise and leadership in the assessment of the patient experience in oncology. She has over 12 years of experience developing and implementing patient relevant endpoint strategies across all areas of oncology. Most recently, Alicyn led Roche/Genentech’s oncology patient-centered outcomes research group, in which capacity she was responsible for novel FDA PRO labeling claims for both Hycela and Hemlibra. Alicyn is a sought-after speaker and thought leader, having been invited to participate in numerous FDA workshops, public forums, and initiatives, including Former Vice President Biden’s Cancer Moonshot Initiative.